GCM
PTGX icon

Graham Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Graham Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,979
Closed -$275K – 1569
2025
Q2 		$275K Buy
+4,979
New +$239K ﹤0.01% 1026
2024
Q3 		– Sell
-7,574
Closed -$262K – 1293
2024
Q2 		$262K Sell
7,574
-10,638
-58% -$312K 0.01% 771
2024
Q1 		$527K Buy
+18,212
New +$496K 0.01% 613
2022
Q4 		– Sell
-53,443
Closed -$450K – 1286
2022
Q3 		$450K Buy
+53,443
New +$506K 0.02% 777

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Graham Capital Management's PTGX Position: Q3 2025 in Review

Graham Capital Management sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 4,979 shares — an estimated $275K sold.

Graham Capital Management first reported a position in PTGX in Q3 2022 and held it in 4 quarters. The position peaked at $527K in Q1 2024. 274 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • Graham Capital Management reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Graham Capital Management sold 4,979 Protagonist Therapeutics shares in Q3 2025, an estimated $275K.
  • Graham Capital Management first reported a position in Protagonist Therapeutics in Q3 2022 and held it in 4 quarters.
  • Graham Capital Management's Protagonist Therapeutics position peaked at $527K in Q1 2024.
  • 274 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.